TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03834493

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Cause of deathFutility Automatic label, confidence 0.9, unverified. How labels are made.
“The study stopped due to futility”

The sponsor’s own words in the registry.

Life of this trial

201920202021202220232024202520262027Registered2019-02-06Started2019-07-28Primary completion2022-12-12Results posted2023-12-20Stopped2026-06-08

Vital statistics

Status
Terminated
Phase
Phase 3
Sponsor
Merck Sharp & Dohme LLC
Sponsor type
Industry
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab; Enzalutamide; Placebo
Participants
1,244
Sites
259
Countries
Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, France, Germany, Hungary and more

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.